How does RU58841 compare with minoxidil and finasteride?

RU58841 is often discussed alongside minoxidil and finasteride, the two treatments most people with pattern hair loss hear about first. They are very different kinds of product. Minoxidil and finasteride are approved medicines. RU58841 is an unapproved research chemical.

Approval status

• Minoxidil applied to the scalp is FDA-approved for pattern hair loss in men and women, and is sold without a prescription in the US.
• Finasteride 1 mg is FDA-approved for pattern hair loss in men only, and needs a prescription.
• RU58841 is not approved as a medicine anywhere. It was licensed for development as PSK-3841, but development stopped after early-phase (Phase II) human trials, and no results from those trials were published. It now circulates only as an unregulated "research chemical". Nobody verifies its identity, purity or strength, and buying or importing it for personal use may be unlawful where you live.

Evidence in people

Minoxidil and finasteride each went through controlled human trials before approval, and each has an approved label that lists its known side effects.

For RU58841, no human trial for hair loss has been published. The published efficacy evidence is preclinical: studies in hamsters (Battmann et al., 1994), balding human scalp grafts kept on mice (De Brouwer et al., 1997), and the bald scalp of stumptailed macaques (Pan et al., 1998).

How they act

• Minoxidil is applied to the scalp. How it helps hair grow is not fully understood.
• Finasteride blocks the enzyme 5-alpha-reductase and lowers DHT levels throughout the body.
• RU58841 is an anti-androgen. In laboratory and animal work it stops DHT from binding to the androgen receptor. It was designed to act only where it is applied, but in people that does not appear to hold. In a small 2026 study, one 30 mg application of an RU58841 product to the scalp of six healthy men left RU58841 and one of its metabolites in their blood, which the authors describe as "considerable systemic exposure" (Okutan et al., 2026). The study did not look at side effects or at repeated or long-term use.

Known risks

• Finasteride: the US label lists sexual side effects, including some that men have reported continued after they stopped, and depression and suicidal thoughts. The UK medicines regulator (MHRA, May 2026) states that finasteride is associated with depression, suicidal thoughts and sexual dysfunction "which may persist after treatment is stopped". The UK regulator (MHRA, May 2026) advises stopping finasteride 1 mg immediately and contacting a doctor if depression or suicidal thoughts develop. Finasteride can harm a male fetus: women who are or may be pregnant must not take it and should not handle crushed or broken tablets (Propecia prescribing information).
• Minoxidil: its approved label lists its known side effects, such as scalp irritation and unwanted hair growth on the face.
• RU58841: no trial has measured its side effects. Because it reaches the blood, it could cause effects seen with other anti-androgens, such as breast tenderness or enlargement and sexual side effects. Anti-androgens can affect the development of a male fetus, so anyone who is pregnant or could become pregnant should not use RU58841. Community members describe acne, scalp irritation and shedding, but these reports are self-reported and involve unverified product.

Combining them

Some community members combine several anti-androgens, including unapproved research chemicals such as RU58841 and pyrilutamide. No study has tested these combinations. Using several drugs that act on the same hormones may raise the chance of side effects. Dutasteride, which some people add, is not FDA-approved for hair loss, and its US label says its sexual side effects may persist after stopping.

Talk to a doctor or pharmacist before starting, stopping or combining any hair-loss treatment, and tell them about anything you use that was bought outside the medical system.

References

Battmann, T., Bonfils, A., Branche, C., Humbert, J., Goubet, F., Teutsch, G., & Philibert, D. (1994). "RU 58841, a new specific topical antiandrogen: a candidate of choice for the treatment of acne, androgenetic alopecia and hirsutism." The Journal of Steroid Biochemistry and Molecular Biology, 48(1), 55-60. https://pubmed.ncbi.nlm.nih.gov/8136306/

De Brouwer, B., Tételin, C., Leroy, T., Bonfils, A., & Van Neste, D. (1997). "A controlled study of the effects of RU58841, a non-steroidal antiandrogen, on human hair production by balding scalp grafts maintained on testosterone-conditioned nude mice." British Journal of Dermatology, 137, 699-702. https://pubmed.ncbi.nlm.nih.gov/9415227/

Pan, H. J., Wilding, G., Uno, H., Inui, S., Goldsmith, L., Messing, E., & Chang, C. (1998). "Evaluation of RU58841 as an anti-androgen in prostate PC3 cells and a topical anti-alopecia agent in the bald scalp of stumptailed macaques." Endocrine, 9(1), 39-43. https://pubmed.ncbi.nlm.nih.gov/9798729/

Okutan, A., Krug, O., Fußhöller, G., Piper, T., & Thevis, M. (2026). "Investigation Into the Metabolism and Elimination Behavior of RU 58841, and Its Influence on the Steroid Profile in Humans." Biomedical Chromatography, 40(10), e70602. https://pubmed.ncbi.nlm.nih.gov/42615108/

Organon. PROPECIA (finasteride) tablets, prescribing information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6f904709-65aa-44ce-b144-b4c8a0416e36

Medicines and Healthcare products Regulatory Agency. (2026, May 11). Finasteride and Dutasteride – updated safety warnings for psychiatric side effects and sexual dysfunction. Drug Safety Update. https://www.gov.uk/drug-safety-update/finasteride-and-dutasteride-updated-safety-warnings-for-psychiatric-side-effects-and-sexual-dysfunction

Waylis. AVODART (dutasteride) capsules, prescribing information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=960797b3-09b1-4d6a-8ece-8b5d918e93e4

U.S. Food and Drug Administration. (2023). Development & Approval Process | Drugs. Retrieved from https://www.fda.gov/drugs/development-approval-process-drugs